Perspectives on Medical Reimbursement By JR Associates Recently, our VP of Global Health Policy, Jo Ellen Slurzberg moderated a compelling roundtable discussion at MDG Boston, a leading member-based community for medical device and technology professionals. This session focused on one of the industry’s most formidable issues: U.S. Healthcare Economics – Innovating Our Way Out of a…
Perspectives on Medical Reimbursement By JR Associates In today’s highly complex healthcare environment, what’s the best way to prepare the next generation of life science innovators? This central question is often top-of-mind among members of the Global Educators Network for Health Innovation Education (GENiE Group). It also provides an overarching framework for the GENiE annual…
Perspectives on Medical Reimbursement By JR Associates What should medical device researchers know about premarket FDA submissions? And what should they understand about reimbursement in early stages of product development? These core questions inspired the first educational seminar hosted by ReGARDD (Regulatory Guidance for Academic Research of Drugs and Devices) in April 2017, where our…
Perspectives on Medical Reimbursement By JR Associates Through the years, our consultants have become popular as featured speakers at a variety of prestigious medical technology forums. But the highlight of our annual events calendar is always the MDMA Coverage, Reimbursement & Health Policy Conference. It is deeply rewarding to connect directly with medical device professionals and discuss critical…
Perspectives on Medical Reimbursement By JR Associates For years, our consultants have been featured speakers at the MDMA Annual Coverage, Reimbursement & Health Policy Conference — and the 2015 conference was no exception. Our Founder and President, Judy Rosenbloom, teamed with VP Health Policy, Jo Ellen Slurzberg, to share their expertise with the medical device manufacturing community in…
Perspectives on Medical Reimbursement By JR Associates When making decisions about medical device coverage, do private insurers take their cues from Medicare (CMS)? Not necessarily, according to a recent study published in the peer-review journal, Health Affairs. According to the research abstract, an analysis of CMS national coverage decisions (NCDs) revealed that: ~50% were equivalent to corresponding private payer policies ~25% were…
Perspectives on Medical Reimbursement By JR Associates “Will my device be reimbursed?” This is one of the most important questions life sciences entrepreneurs must consider when developing new medical technology. But in today’s dynamic and complex healthcare environment, clear answers can be elusive. Harvard Innovation Lab recently invited our VP of Global Health Policy, Jo Ellen Slurzberg, to help clarify…
Perspectives on Medical Reimbursement By JR Associates Coverage. Coding. Payment. These three factors deeply influence reimbursement for every new medical technology product. But there are no “cookie cutter” solutions. Because the reimbursement landscape is so complex and time consuming, it’s smart to start preparing for reimbursement as early as possible in the business planning and product development process. But…
